Ozempic boosts cardiometabolic markers, falls short for fibrosis in NASH-related cirrhosis
LONDON — Ozempic improved cardiometabolic parameters and markers of liver injury yet failed to improve liver fibrosis in patients with nonalcoholic steatohepatitis and compensated cirrhosis, according to late-breaker data presented here.“Patients with NASH and compensated cirrhosis are at a higher risk of liver-related and all-cause morbidity and mortality,” Rohit Loomba, MD, MHSc, director of hepatology and the NAFLD Research Center at UC San Diego School of Medicine, told attendees at the International Liver Congress. “In a previous phase 2b, placebo-controlled studyRead More
